Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Chronic cutaneous lupus erythematosus (CCLE) is a form of cutaneous lupus erythematosus (CLE) that includes five different forms: discoid lupus erythematosus (DLE), chilblain lupus, hypertrophic or verrucous lupus erythematosus, lupus erythematosus tumidus, and lupus erythematosus panniculitis.
Biomarker and diagnostic research for chronic cutaneous lupus erythematosus has been reported in the published literature.
7 clinical trials registered, 1 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 4 PHASE3, 2 PHASE2, 1 PHASE1. Research is primarily industry-sponsored.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07470970](https://clinicaltrials.gov/study/NCT07470970) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 12:41 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about chronic cutaneous lupus erythematosus
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
PHASE3 |
EMD Serono Research & Development Institute, Inc. |
UNKNOWN |
[NCT06044337](https://clinicaltrials.gov/study/NCT06044337) | A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | PHASE3 | Biogen | ENROLLING_BY_INVITATION |
[NCT05531565](https://clinicaltrials.gov/study/NCT05531565) | A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | PHASE2 | Biogen | ACTIVE_NOT_RECRUITING |
[NCT07355218](https://clinicaltrials.gov/study/NCT07355218) | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) | PHASE3 | EMD Serono Research & Development Institute, Inc. | RECRUITING |
[NCT06013995](https://clinicaltrials.gov/study/NCT06013995) | A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus | PHASE1 | Bristol-Myers Squibb | UNKNOWN |
111 publications have been identified in PubMed for chronic cutaneous lupus erythematosus. Research spans Case Report / Case Series (33%), Review / Meta-Analysis (32%), and Epidemiology / Natural History (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 37 | 33% |
Research summaries | 36 | 32% |
Disease patterns and progression | 16 | 14% |
Laboratory research | 9 | 8% |
Testing and diagnosis research | 8 | 7% |
Other research | 2 | 2% |
Clinical study results | 2 | 2% |
New treatment approaches | 1 | 1% |
Perazzolli G (2026). [PMID: 41625144](https://pubmed.ncbi.nlm.nih.gov/41625144/). *SAGE Open Med Case Rep*. [Case Report / Case Series]
Xiong W (2026). [PMID: 40982400](https://pubmed.ncbi.nlm.nih.gov/40982400/). *Dermatology*. [Review / Meta-Analysis]
Olvera-Rodriguez V (2026). [PMID: 40987500](https://pubmed.ncbi.nlm.nih.gov/40987500/). *Pediatr Dermatol*. [Case Report / Case Series]
Muñoz-Barba D (2026). [PMID: 41054977](https://pubmed.ncbi.nlm.nih.gov/41054977/). *J Dermatol*. [Diagnostic / Biomarker]
Glennon CM (2026). [PMID: 41251635](https://pubmed.ncbi.nlm.nih.gov/41251635/). *Am J Kidney Dis*. [Review / Meta-Analysis]
Wang XM (2026). [PMID: 41575073](https://pubmed.ncbi.nlm.nih.gov/41575073/). *J Eur Acad Dermatol Venereol*. [Case Report / Case Series]
Israr Ul Haq M (2026). [PMID: 41822629](https://pubmed.ncbi.nlm.nih.gov/41822629/). *Cureus*. [Case Report / Case Series]
Pan Y (2026). [PMID: 41730565](https://pubmed.ncbi.nlm.nih.gov/41730565/). *Lupus Sci Med*. [Epidemiology / Natural History]
Mohammed SR (2026). [PMID: 41716945](https://pubmed.ncbi.nlm.nih.gov/41716945/). *Case Rep Rheumatol*. [Diagnostic / Biomarker]
Alexandru IC (2026). [PMID: 41751359](https://pubmed.ncbi.nlm.nih.gov/41751359/). *Biomedicines*. [Review / Meta-Analysis]
AI-curated news mentioning chronic cutaneous lupus erythematosus
Updated Mar 30, 2026
Biogen's drug for cutaneous lupus erythematosus shows promising results in reducing disease activity, marking a significant advancement in their immunology and inflammation pipeline. Analysts view this as a crucial derisking step for the company's future prospects.